Maxcyte, Inc.

31 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2028

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 11, 2026
The maintenance fee for Methods and compositions for generating stable transfected cells (US 10,316,335) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
1 fee due Mar 15, 2027
The maintenance fee for Engineering and delivery of therapeutic compositions of freshly isolated cells (US 9,132,153) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,991,559	Computerized electroporation In force Term ends Aug 2, 2028 · From the USPTO record	In force	Term ends Aug 2, 2028	From the USPTO record
US 9,132,153	Engineering and delivery of therapeutic compositions of freshly isolated cells In force Ends no later than Apr 9, 2029 · From the USPTO record	In force	Ends no later than Apr 9, 2029	From the USPTO record
US 9,669,058	Engineering and delivery of therapeutic compositions of freshly isolated cells In force Ends no later than Apr 9, 2029 · From the USPTO record	In force	Ends no later than Apr 9, 2029	From the USPTO record
US 10,660,917	Engineering and delivery of therapeutic compositions of freshly isolated cells In force Ends no later than Apr 9, 2029 · From the USPTO record	In force	Ends no later than Apr 9, 2029	From the USPTO record
US 9,546,350	Methods and devices related to a regulated flow electroporation chamber In force Term ends Jun 12, 2029 · From the USPTO record	In force	Term ends Jun 12, 2029	From the USPTO record
US 8,450,112	Engineering and delivery of therapeutic compositions of freshly isolated cells In force Term ends Jul 13, 2030 · From the USPTO record	In force	Term ends Jul 13, 2030	From the USPTO record
US 10,316,335	Methods and compositions for generating stable transfected cells In force Term ends Feb 14, 2035 · From the USPTO record	In force	Term ends Feb 14, 2035	From the USPTO record
US 11,608,511	Methods for Modifying Genomic DNA In force Ends no later than Apr 15, 2036 · Medium confidence	In force	Ends no later than Apr 15, 2036	Medium confidence
US D923,199	Electroporation device In force Term ends Jun 22, 2036 · From the USPTO record	In force	Term ends Jun 22, 2036	From the USPTO record
US D923,200	Electroporation device In force Term ends Jun 22, 2036 · From the USPTO record	In force	Term ends Jun 22, 2036	From the USPTO record

10 of 31 patents shown.

Pro members see all 31.

Pro members: see all 31 patents

Also on record, not counted in the 31: 2 lapsed for an unpaid fee · 9 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 3 abandoned · 12 no status recorded

List them